Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinoma.
Cancer medicine（2023）
摘要
The efficacy and safety of lenvatinib are similar to A + B as a first-line systemic therapy for unresectable HCC.
更多查看译文
关键词
adverse event,atezolizumab plus bevacizumab,hepatocellular carcinoma,lenvatinib,survival
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要